Drug Treatment Associated with Heart Valve Replacement
Tóm tắt
This article reviews a number of specific pharmacological considerations for patients with prosthetic heart valves. All patients with mechanical heart valves should be anticoagulated. In the past, an International Normalised Ratio (INR) of 2.5 to 4.5 has been recommended. Recent nonrandomised studies have suggested that a patient with a prosthetic valve who is at low risk for thromboembolic events could have an INR ranging from 1.8 to 3.5. The lower end of this range should only be used for patients at higher than average risk of haemorrhage, until randomised data show that levels below 2.5 may be applied universally. In high-risk patients (particularly those with previous thromboembolic events) low dose aspirin should be added. During noncardiac surgery, a patient at low risk for thromboembolic events could be managed by discontinuing anticoagulation 3 days before the operation, with warfarin recommenced as soon as possible afterwards. Perioperative heparinisation would be appropriate in a higher risk patient. Women with prosthetic heart valves wishing to become pregnant should be converted to the use of twice-daily subcutaneous heparin injections. Patients with bioprosthetic valves can be managed without anticoagulation unless they have some other reason to require it. Patients at high risk should be treated with aspirin or warfarin. Thrombolytic therapy for acute valve thrombosis should be used for those who are haemodynamically compromised and therefore have a high risk of mortality from operative intervention. All patients with prosthetic heart valves undergoing invasive procedures potentially causing bacteraemia should receive antibiotic prophylaxis for endocarditis. The actual drugs used depend on the likely nature of the bacteraemia, and any possible patient hypersensitivity.
Tài liệu tham khảo
Hodam R, Starr A, Herr R, et al. Early clinical experience with cloth-covered valvular prostheses. Ann Surg 1969; 170: 471–82.
Hodam R, Anderson R, Starr A, et al. Further evaluation of the composite seat cloth-covered aortic prosthesis. Ann Thorac Surg 1971; 12: 621–38.
Isom OW, Williams CD, Falk EA, et al. Evaluation of anticoagulant therapy in cloth-covered prosthetic valves. Circulation 1973; 48 Suppl. 3: 48–50.
Starr A, Bonchek LI, Anderson RP, et al. Late complications of aortic valve replacement with cloth-covered, composite-seat prostheses: a six-year appraisal. Ann Thorac Surg 1975; 19: 289–300.
Fuster V, Pumphrey CW, McGoon MD, et al. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10–19 year follow-up. Circulation 1982; 66: 157–61.
Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102: 445S–55S.
Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51: 479–85.
Poller L. A simple nomogram for the derivation of international normalised ratios for the standardisation of prothrombin times. Thromb Haemost 1988; 60: 18–20.
Starr A. Ball valve prosthesis: a perspective after 22 years. In: DeBakey ME, editor. Advances in cardiac valves: clinical perspectives. New York: Yorke Medical Books, 1983; 1–13.
Cohn LH. Thromboembolism in different anatomical positions: aortic, mitral and multiple valves. In: Rabago G, Cooley DA, editors. Heart valve replacement and future trends in cardiac surgery. New York: Futura Publishing Co. Ltd., 1987: 259.
Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635–41.
Loeliger EA, Poller L, Samama M, et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985; 54: 515–7.
Davidson J, Colvin BT, Barrowcliffe IW, et al. Guidelines on oral anticoagulation. 2nd ed. British Society for Haematology. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force. J Clin Pathol 1990; 43: 177–83.
Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102: 312S–26S.
DiSesa VJ, Collins Jr JJ, Cohn LH. Hematological complications with the St. Jude valve and reduced-dose coumadin. Ann Thorac Surg 1989; 48: 280–3.
Nair CK, Mohiuddin SM, Hilleman DE, et al. Ten-year results with the St. Jude Medical prosthesis. Am J Cardiol 1990; 65: 217–25.
Kratz JM, Crawford Jr FA, Sade RM, et al. St. Jude prosthesis for aortic and mitral valve replacement: a ten-year experience. Ann Thorac Surg 1993; 56: 462–8.
Wilson DB, Dunn MI, Hassanein K. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 1991; 100: 1553–7.
Crawford Jr FA, Kratz JM, Sade RM, et al. Aortic and mitral valve replacement with the St. Jude Medical prosthesis. Ann Surg 1984; 199: 753–61.
Turpie AG, Gunstensen J, Hirsh J, et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242–5.
Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428–32.
Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427–31.
Björk VO, Hanze A. Ten years’ experience with the Björk-Shiley tilting disc valve. J Thorac Cardiovasc Surg 1979; 78: 331–42.
Beaudet RL, Poirier NL, Doyle D, et al. The Medtronic-Hall cardiac valve: 71/2 years’ clinical experience. Ann Thorac Surg 1986; 42: 644–50.
Eberlein U, von der Emde J, Rein J, et al. Thromboembolic and bleeding complications after mitral valve replacement. Eur J Cardiothor Surg 1990; 4: 605–12.
Horskotte D, Korfer R, Seipel L, et al. Late complications in patients with Bjork-Shiley and St. Jude Medical heart valve replacement. Circulation 1983; 68: 175–84.
Czer LSC, Chaux A, Matloff JM, et al. Ten-year experience with the St. Jude Medical valve for primary valve replacement. J Thorac Cardiovasc Surg 1990; 100: 44–55.
Cortina JM, Martinell J, Artiz V, et al. Comparative clinical results with Omniscience (STM1), Medtronic-Hall, and Björk-Shiley convexo-concave (70 degrees) prostheses in mitral valve and reduced-dose coumadin. Ann Thorac Surg 1986; 91: 174–83.
Vallejo JL, Gonzalez-Santos JM, Albertos J, et al. Eight years’ experience with the Medtronic-Hall valve prosthesis. Ann Thorac Surg 1990; 50: 429–36.
Vogt S, Hoffmann A, Roth J, et al. Heart valve replacement with the Björk-Shiley and St. Jude Medical protheses: a randomized comparison in 178 patients. Eur Heart J 1990; 11: 583–91.
Sethia B, Turner MA, Lewis S, et al. Fourteen years’ experience with the Björk-Shiley tilting disc prosthesis. J Thorac Cardiovasc Surg 1986; 91: 350–61.
Kopf GS, Hammond GL, Geha AS, et al. Long-term performance of the St. Jude Medical valve: low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 1987; 76 Suppl. 3: III–132.
Saour J, Gallus A. Warfarin: is it time to reduce target ranges again? Aust N Z J Med 1993; 23: 692–6.
Antunes MJ. Isolated replacement of a prosthesis or a bioprosthesis in the aortic valve position. Am J Cardiol 1987; 59: 350–2.
Fitzpatrick MA, McCone F. An audit of anticoagulation and endocarditis prophylaxis after heart valve surgery. N Z Med J 1991; 104: 85–8.
Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10 (5): 381–94.
Tanay A, Yust I, Brenner S, et al. Dermal vasculitis due to coumadin sensitivity. Dermatologica 1982; 165: 178–85.
Eby CS. Warfarin-induced skin necrosis. In: Penner JA, Hassouna HI, editors. Hematology/oncology clinics of North America. Philadelphia: WB Saunders Co., 1993: 1291–300.
Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: observations in 180 operations. JAMA 1978; 239: 738–9.
Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves: subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976; 92: 162–7.
Lutz DJ, Noller KL, Spittell Jr JA, et al. Pregnancy and its complications following cardiac valve prostheses. Am J Obstet Gynecol 1978; 131: 460–8.
Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1–17.
Weinstein GS, Mavroudis C, Ebert PA. Preliminary experience with aspirin for anticoagulation in children with prosthetic cardiac valves. Ann Thorac Surg 1982; 33: 549–53.
McGrath LB, Gonzalez Lavin L, Eldredge WJ, et al. Thromboembolic and other events following valve replacement in a pediatric population treated with antiplatelet agents. Ann Thorac Surg 1987; 43: 285–7.
Brott WH, Zajtchuk R, Bowen TE, et al. Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis: prospective study with the Model 2320 Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 1981; 81: 632–5.
Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamoleaspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059–63.
Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537–41.
Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524–9.
Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85–91.
Chesebro JH, Fuster V, Danielson GK, et al. Time-related and chronic risk of thromboembolism after bioprosthetic valve replacement. Circulation 1985; 72 Suppl. 3: 209.
Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic valves. J Am Coll Cardiol 1986; 8: 41B–56B.
Vidne B, Erdman S, Levy MS. Thromboembolism following heart valve replacement by prosthesis: survey amoung 365 consecutive patients. Chest 1973; 63: 713–7.
Tasrini J, Scheffer J, Vaislic C, et al. Role of thrombolytic treatment in thrombosis of valvular prosthesis: apropos of 2 cases and review of world literature. Arch Mal Coeur 1984; 77: 1108–13.
Witchitz S, Veyrat C, Moisson P, et al. Fibrinolytic treatment of thrombus on prosthetic heart valves. Br Heart J 1980; 44: 545–54.
Oage A, Gateau P, Roudant R, et al. Thrombolytic treatment in thromboses of heart valve prosthesis: 3 cases [letter]. Nouv Presse Med 1980; 9: 3186–7.
Nagy ES, Fazakas S, Gajal T, et al. Successful thrombolytic of thrombosis caused by the Bjork-Shiley mitral valve prosthesis. Orv Hetil 1981; 122: 2161–7.
Bassand JP, Becqaue O, Bernard Y, et al. Early post-operative (10th day) thrombosis of a Starr mitral prosthesis: successful fibrinolytic treatment. Arch Mal Coeur 1992; 85: 349–56.
Olson GW, Copeland RB. Emergency fibrinolytic treatment of thrombosed prosthetic heart valves [letter]. Lancet 1982; 1: 1122.
Baglin JY, Diebold B, Henin D, et al. Thrombosis of a valve prosthesis: fatal cerebral embolism during thrombolytic treatment. Arch Mal Coeur 1983; 76: 1077–80.
Gagnon RM, Beaudet R, Lemire J, et al. Streptokinase throm-bolysis of a chronically thrombosed mitral prosthetic valve. Cathet Cardiovasc Diagn 1984; 10: 5–10.
Drauer RA. Successful streptokinase therapy of prosthetic aortic valve thrombosis. Am Heart J 1984; 108: 605–6.
Schwartz L, Colson M, Glynn M, et al. Thrombosis of a prosthetic valve managed by thrombolysis: a case report. Can J Surg 1985; 28: 34–8.
Czer LS, Weiss M, Bateman TM, et al. Fibrinolytic therapy of St Jude valve thrombosis under guidance of digital cinefluoroscopy. J Am Coll Cardiol 1985; 5: 1244–9.
Ledaid LD, Ohayon JP, Colle JP, et al. Acute thrombotic obstruction of disc valve prosthesis: diagnostic considerations and fibrinolytic treatment. J Am Coll Cardiol 1986; 7: 743–51.
Fitzpatrick MA, Ikram H, Ilsley C. Acute thrombotic obstruction of a mitral valve prosthesis: the role of thrombolytic therapy. Aust N Z J Med 1988; 18: 795–7.
Ayuso LA, Juffe A, Rufilances JJ, et al. Thrombectomy: surgical treatment of the thrombosed Bjorke-Shiley prosthesis. J Thorac Cardiovasc Surg 1982; 84: 906–10.
Copans H, Lakier JB, Kinsley RH, et al. Thrombosed Bjork-Shiley mitral prostheses. Circulation 1980; 61: 169–74.
Sherman DG, Dyken ML, Fisher M, et al. Cerebral embolism. Chest 1986; 89: 82S–98S.
Hay DR, Ellis-Pegler RB, Faoagali J, et al. Prevention of infective endocarditis associated with dental treatment and other medical intervention. NZ Med J 1985; 98: 1046–9.
Shulman ST, Amren DP, Bisno AL, et al. Prevention of bacterial endocarditis. Circulation 1984; 70: 1123A–7A.
Therapeutic Advisory Committee of the Australian Dental Association. Prevention of infective endocarditis associated with dental treatment and dental disease. Aust Dental J 1980; 25: 51–5.
Working Party of the British Society for Antimicrobial Chemotherapy. Antibiotic prophylaxis of infective endocarditis. Lancet 1982; 2: 1323–6.
Levy RJ, Schoen FJ, Lund SA, et al. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy: experimental studies of optimal dosages and therapeutic durations. J Thorac Cardiovasc Surg 1987; 94: 551–7.
Levy RJ, Hawley MA, Schoen FJ, et al. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats. Circulation 1985; 71: 349–56.
Bichler J, Fritz H. Hirudin, a new therapeutic tool? Ann Hematol 1991; 63: 67–76.